Vanqua Bio to Present Pre-Clinical Data on VQ-101, a Novel GCase Activator For The Treatment of GBA-Parkinson’s Disease
27 Feb 2024
Phase 1
Posters to be presented atthe AD/PD™ 2024 Conference
CHICAGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, which will be held in Lisbon, Portugal and virtually from March 5-9.
“We created Vanqua Bio with the aim of developing innovative therapies capable of effectively slowing or halting the progression of neurodegenerative disorders, including GBA-PD, which is the largest genetically defined subset of Parkinson’s disease,” said Jim Sullivan, PhD, Co-founder and Chief Executive Officer of Vanqua Bio. “We look forward to discussing the pre-clinical characterization of our clinical stage program, VQ-101, a brain-penetrant small molecule allosteric activator of GCase. Furthermore, we look forward to sharing data on the development of a live cell GCase activity assay, which has enabled measurement of GCase activation in our preclinical systems and will be used to assess GCase activation in our Phase 1 trial.”
Poster presentations:
Title: VQ-101, A Small Molecule Allosteric Activator of Glucocerebrosidase, Demonstrates Neuroprotection in Models of GBA-Parkinson’s Disease and Robust In-Vivo Target Engagement
Date and time: March 8-9
Presenter: Daniel Ysselstein
Title: Development and Testing of a Glucocerebrosidase Activity Assay to Evaluate Target Engagement of Allosteric GCase Activators in Whole Blood Samples
Date and time: March 8-9
Presenter: Daniel Ysselstein
About Vanqua Bio
Founded in 2019 and headquartered in Chicago, Vanqua Bio is a biopharmaceutical company dedicated to discovering and developing next-generation medicines that have the potential to transform the lives of patients with neurodegenerative diseases. Our technology platform utilizes human genetics and patient-derived neuronal cells to identify, validate, and clinically translate novel disease pathways associated with lysosomal dysfunction or aberrant activation of the innate immune system. Initially, we are targeting glucocerebrosidase (GCase) as a potential treatment for Parkinson’s disease (PD). Additional programs address overactivation of the innate immune system in central and peripheral neurodegenerative disorders, including Alzheimer’s disease. For more information, go to .
Media Contact
Alyssa Paldo
FINN Partners
alyssa.paldo@finnpartners.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.